| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-04-09 | GOLDMAN SACHS GROUP INC | Vincerx Pharma, Inc. | 631,490 | 3.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Long Focus Capital Management, LLC | Vincerx Pharma, Inc. | 1,098,753 | 5.1% | EDGAR |
| SC 13G/A | 2024-02-13 | Affinity Asset Advisors, LLC | Vincerx Pharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2024-02-13 | BANK OF AMERICA CORP /DE/ | Vincerx Pharma, Inc. | 1,082,863 | 5.1% | EDGAR |
| SC 13G/A | 2024-02-05 | GOLDMAN SACHS GROUP INC | Vincerx Pharma, Inc. | 1,709,656 | 8.0% | EDGAR |
| SC 13G | 2023-02-14 | Long Focus Capital Management, LLC | Vincerx Pharma, Inc. | 1,414,951 | 6.7% | EDGAR |
| SC 13G/A | 2023-02-13 | Affinity Asset Advisors, LLC | Vincerx Pharma, Inc. | 1,492,771 | 7.0% | EDGAR |
| SC 13G/A | 2023-02-10 | GOLDMAN SACHS GROUP INC | Vincerx Pharma, Inc. | 2,147,849 | 10.1% | EDGAR |
| SC 13G/A | 2023-02-10 | Rubric Capital Management LP | Vincerx Pharma, Inc. | 386,719 | 1.8% | EDGAR |
| SC 13G | 2023-02-08 | GOLDMAN SACHS GROUP INC | Vincerx Pharma, Inc. | 2,076,874 | 9.8% | EDGAR |
| SC 13G/A | 2022-12-29 | Flynn James E | Vincerx Pharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | RTW INVESTMENTS, LP | Vincerx Pharma, Inc. | 741,236 | 3.5% | EDGAR |
| SC 13G/A | 2022-02-14 | TANG CAPITAL PARTNERS LP | Vincerx Pharma, Inc. | 1,030,634 | 4.9% | EDGAR |
| SC 13G/A | 2022-02-14 | PUTNAM INVESTMENTS LLC | Vincerx Pharma, Inc. | - | - | EDGAR |
| SC 13G/A | 2022-02-11 | Affinity Asset Advisors, LLC | Vincerx Pharma, Inc. | 1,135,365 | 5.4% | EDGAR |
| SC 13G | 2022-02-10 | Rubric Capital Management LP | Vincerx Pharma, Inc. | 2,107,000 | 10.0% | EDGAR |
| SC 13G | 2021-11-22 | Affinity Asset Advisors, LLC | Vincerx Pharma, Inc. | 1,076,220 | 5.1% | EDGAR |
| SC 13G | 2021-09-28 | Flynn James E | Vincerx Pharma, Inc. | 1,379,310 | 6.6% | EDGAR |
| SC 13G | 2021-08-04 | SAGE RHINO CAPITAL LLC | Vincerx Pharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-02-16 | CITADEL ADVISORS LLC | Vincerx Pharma, Inc. | - | 4.5% | EDGAR |